Results were announced from a phase 3 study evaluating an investigational intramuscular (IM) formulation of ibalizumab-uiyk for the treatment of heavily treatment-experienced adults with ...
The approval for IM use was based on data from an open-label, crossover study that assessed the bioequivalence of single doses of 125mcg of Plegridy administered as an SC and IM injection. The Food ...
The US Food and Drug Administration (FDA) has approved intramuscular (IM) administration of peginterferon β-1a (Plegridy, Biogen) for patients with relapsing forms of multiple sclerosis (MS). "The new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback